What Is Regulatory Intelligence Software for Medical Devices?

The definition in one sentence

Regulatory intelligence software continuously collects, consolidates and cross-references what regulators and the open market are saying about your medical devices — adverse events, recalls, safety notices, enforcement actions and unauthorized listings — so your team works from one current view instead of a dozen government websites.

The emphasis is on external signals. Your quality system knows what's happening inside your company — complaints received, CAPAs opened, audits passed. Regulatory intelligence covers everything happening outside it: what the FDA, MHRA, Health Canada and their peers have published about your devices (and your competitors'), and where your products are surfacing on the open market.

Why the category exists

Three pressures created it:

• Fragmentation. A manufacturer selling into the US, UK, EU, Canada and Switzerland answers to at least six regulatory publishers — openFDA, MHRA, Health Canada, EU Safety Gate, Swissmedic and EUDAMED — each with its own site, format, search interface and update rhythm. None republishes the others. (Our guide to monitoring beyond the FDA details what each one publishes.)
• Rising obligations. EU MDR made post-market surveillance an explicit, documented, continuous duty rather than a background activity — with reports and evidence a Notified Body actually reviews. FDA expectations under 21 CFR 820 point the same direction.
• The open market went online. Devices now resurface on eBay, Google Shopping and medical resale sites like DotMed and LabX — diverted stock, decommissioned hospital equipment, occasionally recalled or investigational units. No regulator watches that for you.

Manual monitoring doesn't survive contact with all three at once. Teams either narrow their scope (usually to FDA-only), lower their frequency (quarterly sweeps), or both — and each choice is a gap with a compliance cost attached.

The four jobs it does

1. Consolidated lookup

Search a device once and see everything at once: safety and enforcement notices, adverse events and registrations from every covered regulator, side by side. This replaces the six-tabs-and-a-spreadsheet workflow entirely — and because the data is continuously ingested rather than fetched live, lookups are fast and repeatable.

2. Continuous monitoring

Watchlists on your device portfolio, checked on a schedule rather than when someone remembers. New signals arrive as notifications — in-app, email or webhooks into your other systems — instead of waiting to be found.

3. Open-market surveillance

The same watchlists applied to resale marketplaces: finding your devices listed by sellers you don't recognise, verifying that a listing really is your device (modern tools use AI image analysis for this), and supporting the takedown process. Our guide to the grey market for medical devices covers why this matters more than most teams expect.

4. Evidence and reporting

Everything found is captured, timestamped and preserved — so the same monitoring that alerts you also builds the defensible record your PMS report or PSUR needs, and answers the auditor's question "how did you know, and when?" with a log rather than a recollection.

How it differs from a QMS or eQMS

The categories are complementary, not competing — and the boundary is worth being precise about:

A regulatory intelligence platform doesn't replace your complaint handling, document control or CAPA process. It feeds them: an adverse-event cluster or a grey-market finding becomes an input to the processes your QMS already runs.

Who uses it

• Regulatory affairs — device lookups across jurisdictions, PMS data collection, report preparation.
• Quality — signal detection feeding trend analysis and CAPA, evidence for audits.
• Brand protection and legal — unauthorized listing detection, seller patterns, evidence preservation for takedowns and disputes.

In smaller manufacturers these are often the same two or three people — which is exactly why consolidation matters more at that size, not less.

What it looks like in practice

Using MedFortis as the concrete example (it's our platform, so this section is also a fair disclosure of where we sit in the category): a regulatory affairs specialist types a device name once and gets consolidated results from openFDA, MHRA, Health Canada, EU Safety Gate, Swissmedic and EUDAMED — adverse events, safety notices and recalls in a single view, with on-demand report annexes for PMS and PSUR submissions. Meanwhile the same device sits on a watchlist that continuously sweeps eBay, Google Shopping, DotMed and LabX; candidate listings are verified by AI image analysis with a confidence score, coordinated sellers are linked into networks, and every confirmed finding is hashed, preserved as a PDF and logged. Alerts land in a notification centre, email or webhooks; access runs through SSO with MFA; and each customer operates in an isolated environment — the things enterprise security reviews ask about.

Where post-market surveillance fits

Post-market surveillance is the compliance obligation; regulatory intelligence is the capability that feeds it. Under EU MDR Articles 83–92, every manufacturer must run a documented PMS system that actively collects exactly the external data this category consolidates — and produce a PMS report or PSUR from it. That's why PMS is usually the first use case a regulatory intelligence platform is bought for, even though the same data serves competitive intelligence and brand protection the day after.